The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,811.00
Ask: 1,811.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 1,805.00
High: 1,812.50
Low: 1,797.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK concocts Pfizer consumer health merger and spin-off

Wed, 19th Dec 2018 07:12

(Sharecast News) - Pharma giants GlaxoSmithKline and Pfizer have struck a deal to combine their consumer health businesses into a joint venture generating £10bn of annual sales, which will later be spun off as a separate listed company.GSK, which will have controlling stake of 68%, said the all-equity combination of the two businesses is expected to generate annual cost savings of £0.5bn by 2022. The savings will come at a cash cost of £0.9bn and non-cash costs of £0.3bn, but the pair plan to cover integration costs by selling off around a net £1bn of assets.Combining brands that include GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advil, Centrum and Caltrate, the FTSE 100 group said it expects the proposed deal to increase its adjusted earnings and free cashflow in the first full year after closing and boost total earnings in the second full year following the closing.Within three years of the creation of the JV, which is expected to close in the second half of 2019, GSK intends to spin off the combined business and float GSK Consumer Healthcare on the London Stock Market. This decision has been based on the view that the new consumer healthcare company will be better able to support a larger degree of leverage than the GSK group currently, allowing for a reduction in the leverage in the remaining group.The proposed deal comes seven months after GSK took full-ownership of its former consumer health joint venture Novartis and just weeks after Glaxo agreed to sell its Indian nutrition business to Unilever for roughly £3.1bn and then to buy oncology-focused Tesaro for around £4bn.GSK chief executive Emma Walmsley, who was promoted from the consumer healthcare business to the top job in April last year, said the Pfizer transaction was a "unique opportunity" to accelerate her plan to reshape the group to improve its competitive performance."Through the combination of GSK and Pfizer's consumer healthcare businesses we will create substantial further value for shareholders. At the same time, incremental cashflows and visibility of the intended separation will help support GSK's future capital planning and further investment in our pharmaceuticals pipeline," she said."With our future intention to separate, the transaction also presents a clear pathway forward for GSK to create a new global Pharmaceuticals/Vaccines company, with an R&D approach focused on science related to the immune system, use of genetics and advanced technologies, and a new world-leading consumer healthcare company.""Ultimately, our goal is to create two exceptional, UK-based global companies, with appropriate capital structures, that are each well positioned to deliver improving returns to shareholders and significant benefits to patients and consumers."GSK, which has agreed to pay a break fee of $900m in the event that the board changes its recommendation or shareholders do not approve the transaction, stated that it remains committed to the current dividend policy and confirms it continues to expect to pay 80p per share in dividends for 2018 and for 2019.Shares in the company rose more than 5% in early trading to 1,527p.Broker Shore Capital said that following the 3 December transaction to acquire Tesaro, the JV was "further evidence of GSK's renewed focus on Pharmaceuticals R&D and believe separation of the group provides an opportunity for further value delivery from the individual entities"."We would estimate that prior to synergies, the partners will earn a circa 4% return on the gross assets contributed to the JV (based on the reported profit before tax), which rises to circa 6% if the annual cost savings of £0.5bn are realised. As such, delivery of the synergies will be important in ensuring an acceptable return on capital in our view."
More News
23 Aug 2023 08:17

GSK gets positive results from shingles trial of Shingrix in China

(Alliance News) - GSK PLC on Wednesday celebrated positive results from the first-ever efficacy trial of its preventative shingles treatment, Shingrix, in China.

Read more
23 Aug 2023 07:04

GSK reports positive results from shingles vaccine trials in China

(Sharecast News) - GSK reported significant positive findings from its first efficacy trial of the 'Shingrix' shingles vaccine in China on Wednesday.

Read more
22 Aug 2023 13:09

UK's Wood Group raises profit forecast on contract wins; shares rise

CFO David Kemp to retire

*

Read more
21 Aug 2023 22:37

US FDA approves Pfizer's maternal RSV vaccine to protect infants

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

Read more
17 Aug 2023 19:53

Charity says HIV drug deal with GSK's ViiV on ice over price secrecy

(Alliance News) - The Doctors Without Borders, or MSF, charity said Thursday a deal aimed to bring long-term preventative HIV treatment to vulnerable populations was on hold after the drugmaker imposed pricing confidentiality.

Read more
17 Aug 2023 11:56

LONDON MARKET MIDDAY: Stocks down over US rate hike worries

(Alliance News) - Stock prices in Europe were lower at midday on Thursday, after the US Federal Reserve warned that a further interest rate hike may be on the cards.

Read more
17 Aug 2023 08:53

LONDON MARKET OPEN: Stocks fall further after hawkish US Fed minutes

(Alliance News) - Stock prices in London opened in the red on Thursday, amid renewed concerns about further US interest rate increases.

Read more
13 Aug 2023 14:06

Sunday newspaper round-up: White Hydrogen, Bank of England, AI

(Sharecast News) - America's Geological survey estimates that if even a small fraction of naturally occurring - and clean or so-called 'white' - hydrogen beneath the earth's surface were recovered, that would last for hundreds of years. Among the backers of the hydrogen industry is Bill Gates, who ploughed $90m into Koloma, a company hunting for natural hydrogen along the US's Midcontinental Rift System. White hydrogen has also been discovered in Europe, in France's Lorraine region. Nonetheless, the true potential of the stuff will hinge on the findings from those early projects, says Philip Ball, research fellow at Keele University. - Guardian

Read more
10 Aug 2023 15:46

UK dividends calendar - next 7 days

Friday 11 August 
Blackrock Latin American Investment Trust PLCdividend payment date
Caffyns PLCdividend payment date
CMC Markets PLCdividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Next 15 Group PLCdividend payment date
Ninety One PLC and Ltddividend payment date
Schroder European Real Estate Investment Trust PLCdividend payment date
Sportech PLCspecial dividend payment date
Telecom Plus PLCdividend payment date
Triad Group PLCdividend payment date
Wincanton PLCdividend payment date
Monday 14 August 
Mountview Estates PLCdividend payment date
Tuesday 15 August 
Tatton Asset Management PLCdividend payment date
Wednesday 16 August 
Murray International Trust PLCdividend payment date
Shoe Zone PLCdividend payment date
Thursday 17 August 
4imprint Group PLCex-dividend payment date
abrdn PLCex-dividend payment date
abrdn Property Income Trust Ltdex-dividend payment date
Anglo American PLCex-dividend payment date
Baillie Gifford UK Growth Trust PLCex-dividend payment date
Berkeley Group Holdings PLCex-dividend payment date
BlackRock Sustainable American Income Trust PLCex-dividend payment date
Bridgepoint Group PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
ConvaTec Group PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
GSK PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
Hiscox Ltdex-dividend payment date
Impact Healthcare REIT PLCex-dividend payment date
Imperial Brands PLCex-dividend payment date
Investec PLC and Ltdex-dividend payment date
iomart Group PLCex-dividend payment date
Keller Group PLCex-dividend payment date
Lancashire Holdings Ltdex-dividend payment date
London Stock Exchange Group PLCex-dividend payment date
Montanaro European Smaller Cos Trust PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Rotork PLCex-dividend payment date
Sabre Insurance Group PLCex-dividend payment date
Schroders PLCex-dividend payment date
Sirius Real Estate Ltddividend payment date
Tritax EuroBox PLCex-dividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
7 Aug 2023 08:12

PRESS: Inflexion among firms looking to buy Haleon's nicotine business

(Alliance News) - Sky News reported on Sunday that Inflexion Private Equity Partners is among suitors for Haleon PLC's Nicotinell anti-smoking aid.

Read more
3 Aug 2023 16:31

GSK Nigeria calls an end to its business, to return cash

ABUJA, Aug 3 (Reuters) - GlaxoSmithKline (GSK) Nigeria said on Thursday it plans to stop doing business after evaluating the options for moving to a third-party distribution model for its drugs and consumer healthcare goods.

Read more
2 Aug 2023 20:45

TOP NEWS: GSK sues Pfizer over patent infingements for RSV vaccine

(Alliance News) - GSK PLC on Wednesday sued Pfizer Inc over patent infringement, alleging Pfizer's respiratory syncytial virus vaccine steals key elements of GSK's version.

Read more
2 Aug 2023 15:14

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in a U.S. court on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 14:28

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 10:41

Sensodyne maker Haleon's shiny forecast signals price hikes unlikely to dent demand

Shares down 1% on slight decline in H1 adj operating margin

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.